Medicine and Dentistry
Zirconium 89
100%
Neoplasm
98%
Vasculotropin A
80%
Bevacizumab
68%
Biodistribution
61%
Tumor Xenograft
60%
Positron Emission Tomography
59%
Positron Emission Tomography
41%
Everolimus
40%
Biological Marker
40%
Ovarian Cancer
40%
Radioactive Tracer
30%
Breast Cancer
20%
Antiangiogenic Activity
20%
Phenylenediamine
20%
Epidermal Growth Factor Receptor 3
20%
Lumretuzumab
20%
Gamma Urogastrone
20%
Mesothelin
20%
Heat Shock Protein 90
20%
Pancreas Tumor
20%
Antibody-Drug Conjugate
20%
Downregulation
20%
Somatomedin C Receptor
20%
Triple Negative Breast Cancer
20%
Programmed Death 1 Receptor
20%
Lymphoid Organ
20%
Pembrolizumab
20%
Ex Vivo
16%
Luminespib
11%
Vascular Tissue Neoplasm
10%
Standardized Uptake Value
7%
Mammalian Target of Rapamycin Inhibitor
7%
Cancer Cell
7%
Enzyme Linked Immunosorbent Assay
7%
Immunohistochemistry
7%
Cell Line
7%
Secretion (Process)
7%
Diagnosis
6%
Lymphatic Tissue
6%
Mechanistic Target of Rapamycin
5%
Ovarian Cancer Cell Line
5%
Breast Tissue
5%
Tumor Angiogenesis
5%
Indium 111
5%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
61%
Vasculotropin A
60%
Zirconium 89
60%
Bevacizumab
48%
Biological Marker
40%
Everolimus
40%
Ovary Cancer
40%
Biodistribution
34%
Antiangiogenic
20%
Triple Negative Breast Cancer
20%
Epidermal Growth Factor Receptor 3
20%
Lumretuzumab
20%
Gamma Urogastrone
20%
Heat Shock Protein 90
20%
Somatomedin C Receptor
20%
Tracer
18%
Luminespib
11%
Vascular Tumor
10%
Mouse
8%
Mammalian Target of Rapamycin Inhibitor
7%
Malignant Neoplasm
5%
Mammalian Target of Rapamycin
5%
Enzyme-Linked Immunosorbent Assay
5%
Bagg Albino Mouse
5%
Keyphrases
Zirconium-89 (89Zr)
22%
Glutathione S-transferase Polymorphisms
20%
Antibody-drug Conjugate
20%
Pancreatic Tumor
20%
IRDye800CW
20%
Tumor Xenograft
20%
Mesothelin
20%
Tumor
20%
Everolimus
20%
89Zr-bevacizumab
20%
Cancer Xenograft Model
20%
Vascular Endothelial Growth Factor
20%
Ovarian Cancer Xenograft
20%
Early Biomarker
20%
Tumor Uptake
15%
Biodistribution
12%
FaDu
11%
Mean Vascular Density
10%
Tracer Injection
7%
Tumor Lysate
7%
H441
6%
Tracer Uptake
5%
Tumor Angiogenesis
5%
SUVmean
5%
Immunohistochemistry
5%
